Overview

Innovation in prenatal care often starts with high-risk populations. In this webinar, we will explore how evolving standards in alloimmunized pregnancy management are being shaped by emerging clinical findings and where traditional monitoring approaches fall short.

The session will introduce an expansion of UNITY’s Fetal Antigen™ testing and highlight UNITY’s leadership as the first and only fetal antigen test powered by cell-free DNA, supporting earlier clinical clarity and more confident monitoring and referral decisions.

What You’ll Learn

• How innovation can expand access to clinically meaningful information for more patients
• What new clinical evidence reveals about limitations of traditional monitoring approaches
• How fetal antigen testing offers a more targeted approach to pregnancy management
• An overview of UNITY’s expanded Fetal Antigen™ testing and streamlined workflow

Unable to attend this session? The same webinar will be presented on March 4th at 4:00 PM PST. Register here to attend.

‍